CompletedNot applicableNCT05613114
Effect of Dalfampridine in Patients With Hereditary Spastic Paraplegia
Studying Autosomal recessive spastic paraplegia type 45
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European University of Lefke
- Principal Investigator
- Ferda SelcukEuropean University of Lefke
- Intervention
- Dalfampridine 10 MG(drug)
- Enrollment
- 8 enrolled
- Eligibility
- All sexes
- Timeline
- 2020 – 2021
Study locations (1)
- Dr. Burhan Nalbantoğlu State Hospital, Nicosia, Cyprus
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05613114 on ClinicalTrials.govOther trials for Autosomal recessive spastic paraplegia type 45
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07417943Neuromodulation to Enhance Motor Function in HSPRahul Sachdeva
- RECRUITINGNCT06936163A Prospective Cohort Study of Surgical Treatment for Foot Deformities in HSPShanghai 6th People's Hospital
- RECRUITINGNCT06844734A Prospective Cohort Study of ITB Treatment for HSPShanghai 6th People's Hospital
- RECRUITINGNANCT06742697Flexibility, Resistance, Aerobic, Movement Execution Training in Adults With Hereditary Spastic ParaplegiaIRCCS Eugenio Medea
- RECRUITINGEARLY PHASE1NCT06478238Calcium Folinate Treatment of Spastic Paraplegia 56Shanghai 6th People's Hospital
- RECRUITINGNCT06553976Spastic Paraplegia - Centers of Excellence Research NetworkBoston Children's Hospital
- RECRUITINGNCT06572046STOP-HSP.Net: a Registry for Hereditary Spastic Paraplegia as an Integration Tool for Future Therapeutic StrategiesIRCCS Fondazione Stella Maris
- RECRUITINGNCT05848271Natural History Study of Patients with HPDL MutationsUniversity of California, San Diego
See all trials for Autosomal recessive spastic paraplegia type 45 →